Meera Mahalingam MBBS, PhD, FRCPath
Professor of Dermatology and Pathology and Laboratory Medicine
Program Director, Dermatopathology Fellowship Training Program
Meera Mahalingam received her medical degree in India (MBBS) and trained in pathology initially in the UK and subsequently in the USA. She also obtained a PhD from the University of London while doing her residency in pathology. She is a board certified pathologist (UK and USA) and a board certified dermatopathologist. Subsequent to completion of the dermatopathology fellowship from BUSM, she joined Quest Diagnostics Inc., Cambridge as consultant dermatopathologist. Meera was recruited to UMass Medical School Center as Associate professor of Pathology and Medicine, Director of Dermatopathology and Program Director of the Dermatopathology Fellowship training Program in 2005 and, to BUSM as Associate professor of Dermatology and Pathology in 2007. Meera was promoted to professor of Dermatology, Pathology and Laboratory Medicine in 2009 and is the Program Director of the Dermatopathology Fellowship training at Boston University School of Medicine, Boston, MA (Fellowship Information Page). She has served on the Board of the American Society of Dermatopathology since 2003 as Director of Quality Assurance and Laboratory Proficiency (2003-07) and pioneered the digital quality assurance program. Editorial boards she serves on include Journal of Cutaneous Pathology (official journal of the American Society of Dermatopathology) where she initiated the journal CME program in 2007 and Modern Pathology (official journal of the United States and Canadian Academy of Pathology). Meera has over a 100 publications in reputed scientific journals such as Cell, Modern Pathology, British Journal of Dermatology, Human Pathology and Histopathology. Her special interests include cutaneous lymphoproliferative disease and on improving diagnostic accuracy of various skin tumors with particular emphasis on atypical pigmented lesions by examining the morphologic features of lesions by light microscopy and utilizing techniques that include the genomic analyses of select mutations affecting the MAP kinase pathway (known to be commonly affected in melanocytic neoplasias) to explore their potential as ancillary methods for diagnosis or prognosis.